{"nctId":"NCT00409838","briefTitle":"A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","startDateStruct":{"date":"2007-04"},"conditions":["Rheumatoid Arthritis"],"count":113,"armGroups":[{"label":"Abatacept and Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Abatacept","Drug: Methotrexate"]},{"label":"Placebo and Methotrexate","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Methotrexate","Drug: Placebo"]},{"label":"Abatacept - Open Label","type":"EXPERIMENTAL","interventionNames":["Drug: Abatacept","Drug: Methotrexate"]}],"interventions":[{"name":"Abatacept","otherNames":["Orencia","BMS-188667"]},{"name":"Methotrexate","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Abatacept","otherNames":["Orencia","BMS-188667"]},{"name":"Methotrexate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Rheumatoid arthritis (RA) for longer than 1 year from the time of the initial diagnosis of RA\n* Patients must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg, and a stable dose for 28 days prior to treatment (Day 1)\n* Methotrexate weekly dose as low as 10 mg is permitted for patients who cannot tolerate higher doses\n\nKey Exclusion Criteria:\n\n* Evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)","description":"The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"42.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With American College of Rheumatology (ACR) ACR50 and ACR70 Response at Day 169","description":"The ACR defines ACR 50 and ACR70 response as a 50% or 70% improvement (compared with baseline values) in tender and swollen joint counts and 50% or 70% improvement in 3 of the remaining 5 core set measures (patient global assessment of pain, patient global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and 1 acute phase reactant value (C-reactive protein).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 20%, 50%, or 70% Improvement From Baseline in American College of Rheumatology (ACR) Core Components","description":"The ACR defines improvement in core components as 20%, 50%, or 70% improvement in tender and swollen joint counts and 3 of the remaining core components: patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, patient self-assessed disability (Health Assessment Questionnaire Disability Index \\[HAQ-DI\\]), and levels of 1 acute phase reactant (C-reactive protein levels or erythrocyte sedimentation rate.) The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning; scale=0 (no disability) to 3 (completely disabled); total possible score=24. The higher the score, the greater the disability.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null},{"groupId":"OG001","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null},{"groupId":"OG001","value":"53.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null},{"groupId":"OG001","value":"44.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"53.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"53.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Scores (DAS) Based on C-reactive Protein (DAS 28 [CRP]) Levels or Erythrocyte Sedimentation Rate (DAS 28[ESR])","description":"Adjusted mean change from baseline. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of rheumatoid arthritis (\\>5.1=high disease activity; \\<3.2=low disease activity; \\<2.6=remission). CRP or ESR give estimations of DAS28 values on a group level. Change from Baseline=Postbaseline - Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"0.17"},{"groupId":"OG001","value":"-1.21","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"0.17"},{"groupId":"OG001","value":"-1.15","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.97","spread":"0.23"},{"groupId":"OG001","value":"-3.13","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Day 169 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score","description":"Adjusted mean change from baseline. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.07"},{"groupId":"OG001","value":"-0.24","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"0.09"},{"groupId":"OG001","value":"-0.37","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"0.10"},{"groupId":"OG001","value":"-0.36","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.09"},{"groupId":"OG001","value":"-0.13","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.10"},{"groupId":"OG001","value":"-0.23","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.09"},{"groupId":"OG001","value":"-0.21","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.11"},{"groupId":"OG001","value":"-0.11","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":"0.11"},{"groupId":"OG001","value":"-0.36","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"0.10"},{"groupId":"OG001","value":"-0.25","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Day 169 in Analysis of Short-Form 36 (SF-36) Health Survey Questionnaire Domains","description":"Adjusted mean change from baseline. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life and comprised of 8 domains( including 4 physical and 4 mental subscales) used to derive the physical and mental component summary scores. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Change from baseline=postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"1.05"},{"groupId":"OG001","value":"2.16","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.18","spread":"1.37"},{"groupId":"OG001","value":"4.36","spread":"1.38"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), Related SAEs and AEs, and Discontinuations Due to SAEs and AEs During the Double-Blind Period","description":"AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"70.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Abatacept Pharmacokinetic (PK) Parameters: Time to Maximum Concentration (Tmax) and Half-Life of Elimination (T-Half)","description":"Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Tmax = the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. T-Half = the biological half-life or elimination half life of a substance is the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.385","spread":"1.0607"},{"groupId":"OG001","value":"1.193","spread":"0.9956"},{"groupId":"OG002","value":"1.325","spread":"1.0351"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183.583","spread":"35.2606"},{"groupId":"OG001","value":"172.451","spread":"28.7270"},{"groupId":"OG002","value":"180.078","spread":"33.4795"}]}]}]},{"type":"SECONDARY","title":"Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)","description":"Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Maximum Concentration (Cmax)= the maximum plasma concentration of the drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241.972","spread":"41.7191"},{"groupId":"OG001","value":"312.591","spread":"63.3026"},{"groupId":"OG002","value":"264.204","spread":"59.0589"}]}]}]},{"type":"SECONDARY","title":"Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)","description":"Area Under the Plasma Concentration-Time Curve (AUC), a measure of drug absorption, in a dosing interval of 28 days from Day 85 to Day 113. Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38940.063","spread":"9731.0561"},{"groupId":"OG001","value":"48283.479","spread":"10283.2572"},{"groupId":"OG002","value":"41881.508","spread":"10743.8152"}]}]}]},{"type":"SECONDARY","title":"Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)","description":"Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Clearance is a pharmacokinetic parameter that describes how quickly drugs are eliminated, metabolized or distributed throughout the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.269","spread":"0.0730"},{"groupId":"OG001","value":"0.240","spread":"0.0460"},{"groupId":"OG002","value":"0.260","spread":"0.0666"}]}]}]},{"type":"SECONDARY","title":"Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)","description":"The volume of distribution of drug at steady state (VSS). Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.064","spread":"0.0165"},{"groupId":"OG001","value":"0.055","spread":"0.0142"},{"groupId":"OG002","value":"0.061","spread":"0.0162"}]}]}]},{"type":"SECONDARY","title":"Summary Statistics of Minimum Observed Serum Concentration (Cmin) for Abatacept","description":"Minimum concentration (Cmin) of Abatacept 500 mg and 750 mg at given time points","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.76","spread":"10.971"},{"groupId":"OG001","value":"52.19","spread":"19.619"},{"groupId":"OG002","value":"42.30","spread":"15.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.96","spread":"11.337"},{"groupId":"OG001","value":"24.42","spread":"7.697"},{"groupId":"OG002","value":"21.31","spread":"10.504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.45","spread":"7.442"},{"groupId":"OG001","value":"20.83","spread":"10.749"},{"groupId":"OG002","value":"18.52","spread":"8.661"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.51","spread":"6.858"},{"groupId":"OG001","value":"22.06","spread":"9.365"},{"groupId":"OG002","value":"18.94","spread":"7.936"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of Abatacept- Number of Participants With Reactivity Toward CTLA4-IG and CTLA4-T at Day 169","description":"Immunogenicity was determined by measuring adult subject sera for reactivity against the whole Abatacept molecule (CTLA4Ig) and CTLA4-T (CTLA4 without the Ig regions).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169","description":"Mean change in surrogate marker mean ESR. A surrogate marker is an indirect measurement of effectiveness. Change from Baseline = postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.0","spread":"2.86"},{"groupId":"OG001","value":"-4.44","spread":"3.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169","description":"Mean change in RF. A surrogate marker is an indirect measurement of effectiveness. Mean change from Baseline = postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.1","spread":"20.52"},{"groupId":"OG001","value":"-12.1","spread":"14.38"}]}]}]},{"type":"PRIMARY","title":"Long-term Extension (LTE) (Open-Label) Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuatons Due to SAEs, Adverse Events (AEs), Related AEs, and Discontinuations Due to AEs","description":"AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE Period: Overall Number of Participants With Positive Results of Immunogenicity Samples","description":"Positive antibody titers were identified by validated enzyme-linked immunosorbent assay results. On-treatment samples were obtained during the LTE period, and posttreatment samples were following the last infusion of study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ACR20, ACR50, and ACR70 Over Time","description":"The ACR 20, ACR50, and ACR70 are based on 20%, 50% and 70% improvement, respectively, (compared with baseline values) in tender and swollen joint counts and on 20%, 50% and 70%, respectively, improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null},{"groupId":"OG001","value":"36.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"37.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"43.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"25.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"34.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":null},{"groupId":"OG001","value":"74.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"53.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"52.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"53.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null},{"groupId":"OG001","value":"36.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"81.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null},{"groupId":"OG001","value":"51.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"62.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"Improvement is measured by an improved response of at least 0.3 units from baseline on the HAQ-DI score. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score","description":"The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.14"},{"groupId":"OG001","value":"-0.53","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Short-Form 36 (SF-36) Physical and Mental Health Summaries","description":"The SF-36 is a 36-item questionnaire used to measure Quality of Life over 8 physically and emotionally based areas: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Answers to each question correspond to a precoded numeric value. An aggregate percentage score is reached for each of the 8 sections and is based on answers to questions. The mean average is worked out for each section. Scores range from 0% (lowest level of functioning) to 100% (highest level of functioning, with higher score indicated increasing levels of functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.34","spread":"1.80"},{"groupId":"OG001","value":"8.48","spread":"1.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":"2.44"},{"groupId":"OG001","value":"7.73","spread":"2.34"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and With EULAR-defined Remission","description":"EULAR defines LDAS as a disease activity score as measured by c-reactive protein (DAS28-CRP) â‰¤3.2 and remission as DAS28-CRP \\<2.6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null},{"groupId":"OG001","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) Scores","description":"The SDAI is the sum of 5 parameters: Tender joint (TJC) and swollen joint(SJC)counts, based on a 28-joint assessment; patient global (PtGA)and physician global assessments (PGA), assessed on 0-10 cm visual analog scale (VAS), on which higher scores=greater affection due to disease activity DA); and C-reactive protein level. SDAI total score=0-86. SDAI \\<=3.3 indicates disease remission, \\>3.4 to 11=low DA, \\>11 to 26=moderate DA, and \\>26=high DA. SJC is assessed at each visit, with no swelling=0, swelling=1. TJC is assessed through identification of joints painful under pressure or to passive motion at each visit, with no tenderness=0, tenderness=1. Higher score=greater affection due to DA. CDAI is sum of 4 parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score=0-76. CDAI \\<=2.8 indicates disease remission, \\>2.8 to 10=low DA, \\>10 to 22=moderate DA, and \\>22=high DA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.84","spread":null},{"groupId":"OG001","value":"-14.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.74","spread":null},{"groupId":"OG001","value":"-29.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.99","spread":null},{"groupId":"OG001","value":"-13.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.79","spread":null},{"groupId":"OG001","value":"-27.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity Score (LDAS) or Who Are in Remission","description":"LDAS is defined as a Disease Activity Score C-reactive protein (DAS28-CRP) level \\<=3.2. Remission is defined as a DAS28-CRP level \\<2.6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null},{"groupId":"OG001","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"38.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Levels of C-reactive Protein (CRP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.85","spread":"0.29"},{"groupId":"OG001","value":"-0.58","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"0.28"},{"groupId":"OG001","value":"-1.23","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"0.51"},{"groupId":"OG001","value":"-1.62","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.91","spread":"0.31"},{"groupId":"OG001","value":"-1.52","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":"0.30"},{"groupId":"OG001","value":"-1.67","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.06","spread":"0.26"},{"groupId":"OG001","value":"-1.77","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.10","spread":"0.28"},{"groupId":"OG001","value":"-1.75","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.23","spread":"0.27"},{"groupId":"OG001","value":"-1.68","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.24","spread":"0.28"},{"groupId":"OG001","value":"-1.88","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.29","spread":"0.28"},{"groupId":"OG001","value":"-1.63","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.24","spread":"0.29"},{"groupId":"OG001","value":"-1.81","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"0.30"},{"groupId":"OG001","value":"-1.76","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.99","spread":"0.33"},{"groupId":"OG001","value":"-1.99","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.06","spread":"0.32"},{"groupId":"OG001","value":"-1.47","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"0.34"},{"groupId":"OG001","value":"-1.86","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.96","spread":"0.33"},{"groupId":"OG001","value":"1.70","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"0.35"},{"groupId":"OG001","value":"-1.81","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"0.33"},{"groupId":"OG001","value":"-1.83","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.95","spread":"0.47"},{"groupId":"OG001","value":"-1.86","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.43","spread":"0.43"},{"groupId":"OG001","value":"-1.68","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Sedimentation Rate","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.60","spread":"2.93"},{"groupId":"OG001","value":"-7.12","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.43","spread":"3.27"},{"groupId":"OG001","value":"-15.14","spread":"3.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.30","spread":"3.09"},{"groupId":"OG001","value":"-20.27","spread":"3.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.85","spread":"3.24"},{"groupId":"OG001","value":"-20.78","spread":"3.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.58","spread":"3.35"},{"groupId":"OG001","value":"-23.86","spread":"3.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.45","spread":"3.34"},{"groupId":"OG001","value":"-24.94","spread":"3.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.30","spread":"3.46"},{"groupId":"OG001","value":"-24.69","spread":"4.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.32","spread":"3.63"},{"groupId":"OG001","value":"-24.90","spread":"4.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.22","spread":"3.74"},{"groupId":"OG001","value":"-27.38","spread":"4.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.80","spread":"3.70"},{"groupId":"OG001","value":"-23.04","spread":"3.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.52","spread":"3.95"},{"groupId":"OG001","value":"-22.91","spread":"4.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.37","spread":"4.13"},{"groupId":"OG001","value":"-18.22","spread":"4.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.61","spread":"3.68"},{"groupId":"OG001","value":"-21.54","spread":"4.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.53","spread":"3.95"},{"groupId":"OG001","value":"-22.09","spread":"4.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.00","spread":"4.59"},{"groupId":"OG001","value":"-20.29","spread":"4.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.93","spread":"5.08"},{"groupId":"OG001","value":"-22.10","spread":"4.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.67","spread":"4.45"},{"groupId":"OG001","value":"-21.89","spread":"4.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.41","spread":"4.83"},{"groupId":"OG001","value":"-23.88","spread":"4.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.81","spread":"6.96"},{"groupId":"OG001","value":"-25.69","spread":"5.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.80","spread":"6.79"},{"groupId":"OG001","value":"-23.33","spread":"5.85"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":55},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","COUGH","HEADACHE","DYSPEPSIA"]}}}